Nardella, Caterina
 Distribuzione geografica
Continente #
NA - Nord America 1.564
EU - Europa 148
AS - Asia 72
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 1.790
Nazione #
US - Stati Uniti d'America 1.561
CN - Cina 43
IT - Italia 27
SE - Svezia 25
GB - Regno Unito 23
FI - Finlandia 19
TR - Turchia 16
BE - Belgio 14
BG - Bulgaria 9
CH - Svizzera 5
SG - Singapore 5
BR - Brasile 4
DE - Germania 4
FR - Francia 3
BN - Brunei Darussalam 2
CA - Canada 2
CZ - Repubblica Ceca 2
HR - Croazia 2
IN - India 2
NL - Olanda 2
PL - Polonia 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
AU - Australia 1
BD - Bangladesh 1
ES - Italia 1
HK - Hong Kong 1
HU - Ungheria 1
JP - Giappone 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
PR - Porto Rico 1
RU - Federazione Russa 1
UA - Ucraina 1
Totale 1.790
Città #
Chandler 289
Fairfield 250
Ashburn 138
Woodbridge 114
Wilmington 101
Houston 95
Seattle 93
Cambridge 76
Princeton 50
San Mateo 43
Ann Arbor 34
Beijing 30
Jacksonville 19
Izmir 16
San Diego 16
Brussels 13
Helsinki 12
London 9
Sofia 9
Trento 8
Dearborn 7
Hefei 5
Zurich 5
New York 4
Edinburgh 3
Nanjing 3
Norwalk 3
São Paulo 3
Acton 2
Amsterdam 2
Atlanta 2
Bandar Seri Begawan 2
Bratislava 2
Brescia 2
Clearwater 2
Dallas 2
Des Moines 2
Kilburn 2
Milan 2
Phoenix 2
Prague 2
Pune 2
San Francisco 2
Schio 2
Warsaw 2
Washington 2
Zagreb 2
Baotou 1
Boardman 1
Bremen 1
Budapest 1
Charlotte 1
Chengdu 1
Como 1
Costa Mesa 1
Falkenstein 1
Hounslow 1
Islington 1
Kemerovo 1
Kuala Lumpur 1
Kunming 1
Los Angeles 1
Manchester 1
Mountain View 1
New Bedfont 1
Ottawa 1
Pitesti 1
Raleigh 1
Redmond 1
Rome 1
Saint Paul 1
San Jose 1
San Juan 1
San Paolo di Civitate 1
Shenyang 1
Taiyuan 1
Tokyo 1
Toronto 1
Vienna 1
Totale 1.518
Nome #
Subtle variations in Pten dose determine cancer susceptibility 101
Of model pets and cancer models: an introduction to mouse models of cancer 94
Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events 86
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer 82
The APL paradigm and the "co-clinical trial" project 79
Differential requirement of mTOR in postmitotic tissues and tumorigenesis 79
Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis 78
Radiolabeled heparan sulfate immobilized on microplate as substrate for the detection of heparanase activity 78
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion 77
Faithfull modeling of PTEN loss driven diseases in the mouse 76
MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells 75
Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis 74
ETS rearrangements and prostate cancer initiation 74
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition 73
Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate 72
Editorial: Precision medicine in oncology 72
Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence 71
A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis 71
Mechanism of Activation of Human Heparanase Investigated by Protein Engineering 71
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer 71
Pro-senescence therapy for cancer treatment 71
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer 63
Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein 61
Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence 45
Circulating RNAs in prostate cancer patients 33
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation 4
null 1
Totale 1.832
Categoria #
all - tutte 9.355
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.355


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201999 0 0 0 0 0 0 0 0 0 16 52 31
2019/2020483 16 9 9 18 16 45 68 100 96 40 50 16
2020/2021333 36 20 79 35 13 47 8 39 7 39 3 7
2021/2022235 20 6 0 18 6 12 4 63 18 42 10 36
2022/2023538 38 65 2 79 55 91 0 63 89 6 38 12
2023/2024104 16 22 7 7 12 21 13 2 4 0 0 0
Totale 1.832